Eli Lilly's rating gets an upgrade to Aa3 by Moody's Ratings
The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is anticipated to be driven by the company's incretin portfolio, which includes ...
Down 65%, Is Viking Therapeutics Stock a Buy on the Dip?
Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...
Newsable Asianet News on MSN21h
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 ...
BioSpace21h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Terns Pharma: I Don't See The Positioning
Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.
FiercePharma18h
Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma
Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...
Research Pinpoints Weakness in Lung Cancer’s Defenses
Researchers discovered the importance of an enzyme that promotes growth of certain lung cancers. Lung cancer is a ...